BiCAR-NK/T cell therapy (Asclepius Technology Company Group (Suzhou) Co., Ltd)

N/A

Report date: 2024/11/22 20:00:28

Base Information

Drug NameBiCAR-NK/T cell therapy (Asclepius Technology Company Group (Suzhou) Co., Ltd)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > NKT cell therapy > Chimeric antigen receptor NKT cell therapy

Mechanisms of ActionNatural killer cell replacementsRoundabout homolog 1 modulatorsT lymphocyte replacements

TargetsRoundabout homolog 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaPending

Originator CompaniesAsclepius Technology Company Group

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAsclepius Technology Company Group

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A